Loading
The PD-L1 antibody atezolizumab shrank tumours in about a quarter of patients with advanced alveolar soft part sarcoma, with responses lasting years in a disease resistant to chemotherapy, and became the first approved treatment for this sarcoma.
Phase 2 study of 52 patients aged 2 and older with advanced alveolar soft part sarcoma treated with atezolizumab every three weeks.
Objective response was 24 percent (37 percent in an updated analysis with longer follow-up), with a median duration of response of over 16 months and stable disease in most others; toxicity was typical of PD-L1 blockade and low grade.
Atezolizumab is the first-line systemic treatment for advanced alveolar soft part sarcoma, a rare, slow-growing but ultimately metastatic sarcoma of young adults for which chemotherapy never worked.
Shares Alveolar soft part sarcoma, Atezolizumab.